3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
beta-Thalassemia
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Anemia
2
Primary Myelofibrosis
1
Higher-risk Myelodysplastic Syndrome
1
Interventions
ruxolitinib
6
Early Intervention, Educational
3
parsaclisib
2
navitoclax
2
liposomal amphotericin B
2
fedratinib
2
Psychiatric Rehabilitation
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Cyclophosphamide
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
selinexor
1
pomalidomide
1
peginterferon alfa-2b
1
peginterferon alfa-2a
1
luspatercept
1
imetelstat
1
fludarabine
1
bomedemstat
1
Whole-Body Irradiation
1
Valacyclovir
1
Therapeutics
1
Tacrolimus
1
Ribavirin
1
Radiotherapy
1
Pharmacogenomic Testing
1
Palivizumab
1
Ondansetron
1
N(4)-oleylcytosine arabinoside
1
Moxifloxacin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Primary Myelofibrosis
×
luspatercept
×
Clear all
NCT04717414
2025-07-10
INDEPENDENCE
Celgene
Phase 3
Active not recruiting
313 enrolled